{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:37:12Z","timestamp":1786628232467,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05810-y","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:56:11Z","timestamp":1786582571000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the role of inflammatory cytokines in obesity-mediated MASLD development and drug target identification"],"prefix":"10.1007","author":[{"given":"Chenhao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"5810_CR1","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1093\/eurheartj\/ehac394","volume":"43","author":"BJ Arsenault","year":"2022","unstructured":"Arsenault BJ (2022) From the garden to the clinic: how Mendelian randomization is shaping up atherosclerotic cardiovascular disease prevention strategies. Eur Heart J 43:4447\u20134449","journal-title":"Eur Heart J"},{"key":"5810_CR2","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/hep.31537","volume":"73","author":"C Barahona Ponce","year":"2021","unstructured":"Barahona Ponce C et al (2021) Gallstones, body mass index, C-reactive protein, and gallbladder cancer: Mendelian randomization analysis of Chilean and European genotype data. Hepatology 73:1783\u20131796","journal-title":"Hepatology"},{"key":"5810_CR3","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41588-021-00892-1","volume":"53","author":"AR Barton","year":"2021","unstructured":"Barton AR, Sherman MA, Mukamel RE, Loh PR (2021) Whole-exome imputation within UK Biobank powers rare coding variant association and fine-mapping analyses. Nat Genet 53:1260\u20131269","journal-title":"Nat Genet"},{"key":"5810_CR4","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1093\/hmg\/ddp357","volume":"18","author":"NL Beer","year":"2009","unstructured":"Beer NL et al (2009) The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18:4081\u20134088","journal-title":"Hum Mol Genet"},{"key":"5810_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.7326\/0003-4819-132-2-200001180-00004","volume":"132","author":"S Bellentani","year":"2000","unstructured":"Bellentani S et al (2000) Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132:112\u2013117","journal-title":"Ann Intern Med"},{"key":"5810_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12092144","author":"SC Coste","year":"2024","unstructured":"Coste SC et al (2024) Metabolic dysfunction-associated steatotic liver disease: the associations between inflammatory markers, TLR4, and cytokines IL-17A\/F, and their connections to the degree of steatosis and the risk of fibrosis. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12092144","journal-title":"Biomedicines"},{"key":"5810_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C et al (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol 69:896\u2013904","journal-title":"J Hepatol"},{"key":"5810_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hep4.1805","volume":"6","author":"CJ Fairfield","year":"2022","unstructured":"Fairfield CJ et al (2022) Genome-wide association study of NAFLD using electronic health records. Hepatol Commun 6:297\u2013308","journal-title":"Hepatol Commun"},{"key":"5810_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41586-022-05289-6","volume":"610","author":"A Filliol","year":"2022","unstructured":"Filliol A et al (2022) Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis. Nature 610:356\u2013365","journal-title":"Nature"},{"key":"5810_CR10","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s42255-020-00287-2","volume":"2","author":"L Folkersen","year":"2020","unstructured":"Folkersen L et al (2020) Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nat Metab 2:1135\u20131148","journal-title":"Nat Metab"},{"key":"5810_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100437","volume":"2","author":"N Ghodsian","year":"2021","unstructured":"Ghodsian N et al (2021) Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. Cell Rep Med 2:100437","journal-title":"Cell Rep Med"},{"key":"5810_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.joca.2020.12.015","volume":"29","author":"D Gill","year":"2021","unstructured":"Gill D, Karhunen V, Malik R, Dichgans M, Sofat N (2021) Cardiometabolic traits mediating the effect of education on osteoarthritis risk: a Mendelian randomization study. Osteoarthritis Cartilage 29:365\u2013371","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"5810_CR13","doi-asserted-by":"publisher","first-page":"6336","DOI":"10.1038\/s41467-020-20079-2","volume":"11","author":"A Gilly","year":"2020","unstructured":"Gilly A et al (2020) Whole-genome sequencing analysis of the cardiometabolic proteome. Nat Commun 11:6336","journal-title":"Nat Commun"},{"key":"5810_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00754-1","volume":"12","author":"RF Hillary","year":"2020","unstructured":"Hillary RF et al (2020) Multi-method genome- and epigenome-wide studies of inflammatory protein levels in healthy older adults. Genome Med 12:60","journal-title":"Genome Med"},{"key":"5810_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1530\/JME-13-0243","volume":"52","author":"Y Ishizuka","year":"2014","unstructured":"Ishizuka Y et al (2014) TRIB1 downregulates hepatic lipogenesis and glycogenesis via multiple molecular interactions. J Mol Endocrinol 52:145\u2013158","journal-title":"J Mol Endocrinol"},{"key":"5810_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.634409","volume":"11","author":"J Lambrecht","year":"2020","unstructured":"Lambrecht J, Tacke F (2020) Controversies and opportunities in the use of inflammatory markers for diagnosis or risk prediction in fatty liver disease. Front Immunol 11:634409","journal-title":"Front Immunol"},{"key":"5810_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1042567","volume":"13","author":"Z Li","year":"2023","unstructured":"Li Z et al (2023) Body mass index, C-reactive protein, and pancreatic cancer: a Mendelian randomization analysis to investigate causal pathways. Front Oncol 13:1042567","journal-title":"Front Oncol"},{"issue":"1","key":"5810_CR18","doi-asserted-by":"publisher","first-page":"11814","DOI":"10.1038\/s41598-024-62742-4","volume":"14","author":"J Li","year":"2024","unstructured":"Li J, Ma X, Yin C (2024) Proteome-wide Mendelian randomization identifies potential therapeutic targets for nonalcoholic fatty liver diseases. Sci Rep 14:11814","journal-title":"Sci Rep"},{"key":"5810_CR19","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65554","author":"Y Liu","year":"2021","unstructured":"Liu Y et al (2021) Genetic architecture of 11 organ traits derived from abdominal MRI using deep learning. Elife. https:\/\/doi.org\/10.7554\/eLife.65554","journal-title":"Elife"},{"key":"5810_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149641","volume":"54","author":"K Mladenic","year":"2024","unstructured":"Mladenic K, Lenartic M, Marinovic S, Polic B, Wensveen FM (2024) The \u201cdomino effect\u201d in MASLD: the inflammatory cascade of steatohepatitis. Eur J Immunol 54:e2149641","journal-title":"Eur J Immunol"},{"key":"5810_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98045","author":"AM Morton","year":"2018","unstructured":"Morton AM et al (2018) Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.98045","journal-title":"JCI Insight"},{"issue":"Suppl 1","key":"5810_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/liv.14355","volume":"40","author":"MD Muthiah","year":"2020","unstructured":"Muthiah MD, Sanyal AJ (2020) Current management of non-alcoholic steatohepatitis. Liver Int 40(Suppl 1):89\u201395","journal-title":"Liver Int"},{"key":"5810_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/joim.13531","volume":"292","author":"R Paternostro","year":"2022","unstructured":"Paternostro R, Trauner M (2022) Current treatment of non-alcoholic fatty liver disease. J Intern Med 292:190\u2013204","journal-title":"J Intern Med"},{"key":"5810_CR24","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1038\/s41467-021-22338-2","volume":"12","author":"R Pazoki","year":"2021","unstructured":"Pazoki R et al (2021) Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes. Nat Commun 12:2579","journal-title":"Nat Commun"},{"key":"5810_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/liv.13972","volume":"39","author":"S Pelusi","year":"2019","unstructured":"Pelusi S, Valenti L (2019) Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease. Liver Int 39:250\u2013256","journal-title":"Liver Int"},{"key":"5810_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj1541","volume":"374","author":"M Pietzner","year":"2021","unstructured":"Pietzner M et al (2021) Mapping the proteo-genomic convergence of human diseases. Science 374:eabj1541","journal-title":"Science"},{"key":"5810_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1527-3466.2006.00033.x","volume":"24","author":"K Prasad","year":"2006","unstructured":"Prasad K (2006) C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 24:33\u201350","journal-title":"Cardiovasc Drug Rev"},{"key":"5810_CR28","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41576-021-00387-z","volume":"22","author":"WR Reay","year":"2021","unstructured":"Reay WR, Cairns MJ (2021) Advancing the use of genome-wide association studies for drug repurposing. Nat Rev Genet 22:658\u2013671","journal-title":"Nat Rev Genet"},{"key":"5810_CR29","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41588-021-00931-x","volume":"53","author":"S Sakaue","year":"2021","unstructured":"Sakaue S et al (2021) A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet 53:1415\u20131424","journal-title":"Nat Genet"},{"key":"5810_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1055\/s-0035-1562943","volume":"35","author":"SK Satapathy","year":"2015","unstructured":"Satapathy SK, Sanyal AJ (2015) Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis 35:221\u2013235","journal-title":"Semin Liver Dis"},{"key":"5810_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","volume":"20","author":"M Sayiner","year":"2016","unstructured":"Sayiner M, Koenig A, Henry L, Younossi ZM (2016) Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis 20:205\u2013214","journal-title":"Clin Liver Dis"},{"key":"5810_CR32","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.1158\/0008-5472.CAN-22-1257","volume":"82","author":"A Singh","year":"2022","unstructured":"Singh A, Mayengbam SS, Yaduvanshi H, Wani MR, Bhat MK (2022) Obesity programs macrophages to support cancer progression. Cancer Res 82:4303\u20134312","journal-title":"Cancer Res"},{"key":"5810_CR33","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1001\/jama.2021.18236","volume":"326","author":"VW Skrivankova","year":"2021","unstructured":"Skrivankova VW et al (2021) Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement. JAMA 326:1614\u20131621","journal-title":"JAMA"},{"key":"5810_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1001324","volume":"7","author":"EK Speliotes","year":"2011","unstructured":"Speliotes EK et al (2011) Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7:e1001324","journal-title":"PLoS Genet"},{"key":"5810_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-018-0175-2","volume":"558","author":"BB Sun","year":"2018","unstructured":"Sun BB et al (2018) Genomic atlas of the human plasma proteome. Nature 558:73\u201379","journal-title":"Nature"},{"key":"5810_CR36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun BB et al (2023) Plasma proteomic associations with genetics and health in the UK Biobank. Nature 622:329\u2013338","journal-title":"Nature"},{"key":"5810_CR37","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/ije\/dyx207","volume":"46","author":"VM Walker","year":"2017","unstructured":"Walker VM, Davey Smith G, Davies NM, Martin RM (2017) Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. Int J Epidemiol 46:2078\u20132089","journal-title":"Int J Epidemiol"},{"key":"5810_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1053\/j.gastro.2010.09.038","volume":"140","author":"CD Williams","year":"2011","unstructured":"Williams CD et al (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140:124\u2013131","journal-title":"Gastroenterology"},{"key":"5810_CR39","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/hep.32728","volume":"77","author":"J Xie","year":"2023","unstructured":"Xie J et al (2023) The associations between modifiable risk factors and nonalcoholic fatty liver disease: a comprehensive Mendelian randomization study. Hepatology 77:949\u2013964","journal-title":"Hepatology"},{"key":"5810_CR40","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1172\/JCI200319451","volume":"112","author":"H Xu","year":"2003","unstructured":"Xu H et al (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821\u20131830","journal-title":"J Clin Invest"},{"key":"5810_CR41","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z et al (2019) Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69:2672\u20132682","journal-title":"Hepatology"},{"key":"5810_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM et al (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73\u201384","journal-title":"Hepatology"},{"key":"5810_CR43","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM et al (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77:1335\u20131347","journal-title":"Hepatology"},{"key":"5810_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z et al (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15:11\u201320","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5810_CR45","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10654-022-00868-3","volume":"37","author":"S Yuan","year":"2022","unstructured":"Yuan S et al (2022) Lifestyle and metabolic factors for nonalcoholic fatty liver disease: mendelian randomization study. Eur J Epidemiol 37:723\u2013733","journal-title":"Eur J Epidemiol"},{"key":"5810_CR46","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1161\/01.ATV.19.4.972","volume":"19","author":"JS Yudkin","year":"1999","unstructured":"Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972\u2013978","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5810_CR47","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/s41588-020-0682-6","volume":"52","author":"J Zheng","year":"2020","unstructured":"Zheng J et al (2020) Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet 52:1122\u20131131","journal-title":"Nat Genet"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05810-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05810-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05810-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:01:49Z","timestamp":1786626109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05810-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":47,"alternative-id":["5810"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05810-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable (the data used in this study are from publicly available databases, which do not require additional ethical approval or informed consent).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (the study does not contain any individual person\u2019s data, and all data are from publicly available databases).","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used ChatGPT in order to improve language and readability. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":4,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}]}}